LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.25 10.62

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.13

Max

1.25

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-34M 68M
Eelmine avamishind	-9.37
Eelmine sulgemishind	1.25

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. veebr 2026, 22:31 UTC

Tulu

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18. veebr 2026, 22:18 UTC

Tulu

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18. veebr 2026, 22:11 UTC

Tulu

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18. veebr 2026, 21:52 UTC

Tulu

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18. veebr 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18. veebr 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18. veebr 2026, 23:34 UTC

Market Talk

Tulu

Brambles' Cost Control Stands Out to Bull -- Market Talk

18. veebr 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18. veebr 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18. veebr 2026, 22:45 UTC

Tulu

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18. veebr 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18. veebr 2026, 22:37 UTC

Tulu

Nutrien 4Q EPS $1.18 >NTR.T

18. veebr 2026, 22:37 UTC

Tulu

Nutrien 4Q Sales $5.34B >NTR.T

18. veebr 2026, 22:35 UTC

Tulu

Pan American Silver 4Q EPS $1.07 >PAAS

18. veebr 2026, 22:35 UTC

Tulu

Pan American Silver 4Q Rev $1.18B >PAAS

18. veebr 2026, 22:30 UTC

Tulu

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18. veebr 2026, 22:29 UTC

Tulu

Kinross Gold 4Q EPS 75c >K.T

18. veebr 2026, 22:22 UTC

Tulu

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18. veebr 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18. veebr 2026, 22:16 UTC

Tulu

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18. veebr 2026, 22:05 UTC

Tulu

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18. veebr 2026, 22:03 UTC

Tulu

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q Sales $929M >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q EPS $1.68 >KALU

18. veebr 2026, 22:00 UTC

Tulu

Kinross Gold 4Q Adj EPS 67c >KGC

18. veebr 2026, 22:00 UTC

Tulu

Kinross Gold 4Q Sales $2.02B >KGC

18. veebr 2026, 21:56 UTC

Tulu

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnangu Konsensus

By TipRanks

Müü

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.